Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs
| Autor: | Suzanne R Morgan, Sam S. Rebello, Charles J Kasiewski, Valeria Chu, Mark H Perrone, Ross G. Bentley, Jeffrey S Bostwick, Robert J. Leadley, Klein Scott I |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
medicine.medical_specialty Time Factors medicine.drug_class Low molecular weight heparin Platelet Glycoprotein GPIIb-IIIa Complex Dogs Fibrinolytic Agents Internal medicine medicine Animals Thrombolytic Therapy Enoxaparin Vascular Patency Dalteparin sodium medicine.diagnostic_test Unstable angina T-plasminogen activator business.industry Heparin Coronary Thrombosis Anticoagulant Hematology medicine.disease Disease Models Animal Therapeutic Equivalency Anesthesia Tissue Plasminogen Activator Cardiology Drug Therapy Combination Female business Enoxaparin sodium Oligopeptides Blood Flow Velocity Platelet Aggregation Inhibitors medicine.drug Partial thromboplastin time |
| Zdroj: | Thrombosis research. 102(3) |
| ISSN: | 0049-3848 |
| Popis: | It is known that a low-molecular-weight heparin (LMWH) is more effective than unfractionated heparin in unstable angina/non-Q-wave myocardial infarction (UA/NQMI) and the platelet GPIIb/IIIa receptors play an important role in acute myocardial infarction (AMI). Therefore, enoxaparin might have a similar advantage over heparin when used with a GPIIb/IIIa antagonist (RPR109891) in coronary thrombolysis. After induction of coronary thrombosis in anesthetized dogs, infusion of saline, enoxaparin, heparin, RPR109891, enoxaparin+RPR109891, or heparin+RPR109891 was initiated followed 15 min later by recombinant tissue plasminogen activator (rt-PA). The incidence of reperfusion in the enoxaparin+RPR109891- and the heparin+RPR109891-treated groups was similar, but time to reperfusion tended to be shorter for enoxaparin versus heparin. Only 43% of the vessels reoccluded in the enoxaparin+RPR109891 group, compared to 100% vessels in the heparin+RPR109891 group. Enoxaparin+RPR109891 maintained flow for a significantly longer time compared to saline, enoxaparin, heparin, and heparin+RPR109891. Enoxaparin+RPR109891 and heparin+RPR109891 increased the template bleeding time by 2- and 3-fold and activated partial thromboplastin time (APTT) by 1.3- and 3-fold, respectively. These data suggest that enoxaparin is more effective and potentially safer than heparin when combined with a GPIIb/IIIa receptor antagonist during rt-PA-induced coronary thrombolysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect